Eli Lilly’s mirikizumab shows promise in Phase III Crohn’s disease trial

Mirikizumab demonstrated significant improvements in Crohn's disease patients.

Vishnu Priyan May 22 2024

Eli Lilly has reported promising results from the Phase III VIVID-1 study of mirikizumab in treating moderately to severely active Crohn's disease.

The randomised, treat-through, double-blind trial assessed the safety and efficacy of mirikizumab versus placebo and ustekinumab, an active control.

It enrolled Crohn's disease patients irrespective of their previous biological failure status.

Trial data revealed that mirikizumab achieved statistically significant and clinically meaningful improvements across various endpoints at one year when compared to placebo.

The therapy met both co-primary endpoints and all major secondary endpoints in week 52.

A higher proportion of patients in the mirikizumab arm achieved clinical response by patient-reported outcomes at week 12 and clinical remission at week 52, as well as endoscopic response, compared to placebo.

The response rates and treatment effects were consistent among bio-naïve patients and those with prior biologic failure.

Notably, 54.1% and 48.4% of patients treated with mirikizumab achieved clinical remission and endoscopic response, respectively, at one year.

When compared to ustekinumab, patients on mirikizumab showed higher rates of combined clinical remission and endoscopic response, especially among those with prior biologic failure.

Mirikizumab also demonstrated nominal statistical significance over ustekinumab in reducing inflammation biomarkers at week 52, although it did not show superiority in endoscopic response.

The safety profile of mirikizumab was in line with the data already reported on ulcerative colitis patients.

Covid-19, anaemia, and injection site reactions were reported to be the most common adverse events in the trial.

The company filed a supplemental biologics licence application for the therapy to treat Crohn's disease with the US Food and Drug Administration and the European Medicines Agency.

Eli Lilly Immunology development senior vice-president Mark Genovese said: “After one year of treatment, more than one-half of patients treated with mirikizumab achieved clinical remission and nearly one-half achieved endoscopic response. Remarkably, the majority of patients who achieved either of these endpoints achieved both together.

“Lilly is committed to developing innovative treatments, like mirikizumab, that may improve upon the standard of care for people impacted by inflammatory bowel disease and immune-mediated diseases.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close